Radius Health (RDUS) Earns “Buy” Rating from Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their buy rating on shares of Radius Health (NASDAQ:RDUS) in a research note released on Thursday morning. The firm currently has a $58.00 price target on the biopharmaceutical company’s stock.
RDUS has been the topic of a number of other reports. Zacks Investment Research lowered shares of Radius Health from a hold rating to a sell rating in a research note on Wednesday, October 4th. BidaskClub raised Radius Health from a strong sell rating to a sell rating in a research report on Wednesday, December 27th. Goldman Sachs Group reissued a neutral rating and set a $45.00 price objective on shares of Radius Health in a research report on Friday, October 6th. Maxim Group reissued a positive rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Finally, Jefferies Group lowered their price objective on Radius Health from $38.00 to $31.00 and set a hold rating for the company in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $48.00.
Shares of Radius Health (RDUS) traded up $1.90 during trading hours on Thursday, reaching $38.02. 1,599,499 shares of the company’s stock were exchanged, compared to its average volume of 974,121. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. The stock has a market capitalization of $1,780.00, a price-to-earnings ratio of -7.00 and a beta of 1.10. Radius Health has a one year low of $24.66 and a one year high of $49.16.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 50,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average cost of $26.25 per share, with a total value of $1,312,500.00. Following the completion of the acquisition, the insider now directly owns 5,698,799 shares of the company’s stock, valued at approximately $149,593,473.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jesper Hoiland purchased 6,800 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was acquired at an average cost of $29.04 per share, with a total value of $197,472.00. Following the completion of the acquisition, the insider now directly owns 12,900 shares of the company’s stock, valued at $374,616. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 158,578 shares of company stock valued at $4,659,916. Corporate insiders own 15.00% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC acquired a new position in Radius Health in the third quarter valued at approximately $110,000. Ameritas Investment Partners Inc. boosted its holdings in Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares in the last quarter. Advisor Group Inc. boosted its holdings in Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares in the last quarter. Amalgamated Bank acquired a new position in Radius Health in the second quarter valued at approximately $211,000. Finally, Principal Financial Group Inc. boosted its holdings in Radius Health by 14.1% in the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 839 shares in the last quarter.
ILLEGAL ACTIVITY NOTICE: “Radius Health (RDUS) Earns “Buy” Rating from Cantor Fitzgerald” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/01/20/radius-health-rdus-earns-buy-rating-from-cantor-fitzgerald.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.